Select Page

Fixed Code

Jubak Picks Portfolio | Click to Expand Live Table

NASDAQ
6426.922
+4.229
+0.066%
 
S&P500
2502.22
+1.62
+0.06%
 
NYSE
12151.795
+18.175
+0.1498%
 
ACAD
37.59
-0.04
-0.11%
 
ADSK
111.78
-0.51
-0.45%
 
ALV
125.21
+0.78
+0.63%
 
BABA
178.14
+0.75
+0.42%
 
DXJR
14.57
0.00
0.00%
 
EUM
18.97
+0.11
+0.58%
 
FANG
95.74
-1.62
-1.66%
 
HAIN
39.6
-0.3
-0.75%
 
HDB
97.23
-0.61
-0.62%
 
INCY
110.85
-4.2
-3.65%
 
IONS
51.32
-0.51
-0.98%
 
ITUB
13.88
+0.1
+0.73%
 
LNG
43.48
-0.43
-0.98%
 
MGM
32.38
-0.68
-2.06%
 
OGXI
0.4
-0.02
-3.85%
 
STO
20
+0.14
+0.70%
 
SYNA
37.98
-1.42
-3.60%
 
TRGP
46.96
+0.14
+0.30%
 
V
105.56
+0.25
+0.24%
 
XYL
64.75
+0.82
+1.28%
 
NASDAQ
6426.922
+4.229
+0.066%
 
S&P500
2502.22
+1.62
+0.06%
 
NYSE
12151.795
+18.175
+0.1498%
 
ACAD
37.59
-0.04
-0.11%
 
ADSK
111.78
-0.51
-0.45%
 
ALV
125.21
+0.78
+0.63%
 
BABA
178.14
+0.75
+0.42%
 
DXJR
14.57
0.00
0.00%
 
EUM
18.97
+0.11
+0.58%
 
FANG
95.74
-1.62
-1.66%
 
HAIN
39.6
-0.3
-0.75%
 
HDB
97.23
-0.61
-0.62%
 
INCY
110.85
-4.2
-3.65%
 
IONS
51.32
-0.51
-0.98%
 
ITUB
13.88
+0.1
+0.73%
 
LNG
43.48
-0.43
-0.98%
 
MGM
32.38
-0.68
-2.06%
 
OGXI
0.4
-0.02
-3.85%
 
STO
20
+0.14
+0.70%
 
SYNA
37.98
-1.42
-3.60%
 
TRGP
46.96
+0.14
+0.30%
 
V
105.56
+0.25
+0.24%
 
XYL
64.75
+0.82
+1.28%
 

     Symbol      Company      Date Added Price
     Then
Target
     Price
Price
     Now
Today's
     Change
Jubak's
     Gain/Loss (%)
Arcos Dorados Holdings Inc. 15.00
SPDR Gold Shares 139.00
Danaher 95.00
Diamondback Energy, Inc. 130.00
ACADIA Pharmaceuticals Inc. 55.00
Autoliv, Inc. 120.00
Synaptics Incorporated 115.00
Alibaba Group Holding Limited 195.00
The Hain Celestial Group, Inc. 62.00
WisdomTree Japan Hedged Real Estate ETF 32.00
HDFC Bank Limited 62.00
Visa Inc. 108.00
Itau Unibanco Holding S.A. 18.00
Ionis Pharmaceuticals, Inc. 65.00
Incyte Corporation 142.00
Cheniere Energy, Inc. 58.00
Targa Resources Corp. 60.00
Xylem Inc. 63.00
Statoil ASA 24.00
MGM Resorts International 26.00
OncoGenex Pharmaceuticals, Inc. 22.00
Arcos Dorados Holdings Inc. (ARCO)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
15.00

Buy Arco Dorados Holdings in my Jubak Picks portfolio

Arco Dorados Holdings (ARCO) is a twofer. The New York traded ADRs of the largest operator of McDonald’s (MCD) franchises in the world, is soaring on the recovery in its two biggest markets Brazil and Argentina.

Posted in ARCO, Breaking News, Buy, Jubak Picks Portfolio | Tagged , , , | Leave a comment

SPDR Gold Shares (GLD)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
139.00

Adding a gold ETF on today’s drop in the metal on hurricane, North Korea relief

I’m adding the SPDR Gold Shares ETF (GLD) to my Jubak Picks and Volatility portfolios today. Gold has sold off today with worries over a new missile test from North Korea in abeyance. And with traders relieved–and apparently surprised–to discover that Hurricane Irma didn’t wash Florida out to sea over the weekend. As I have noted over the last few days the likelihood is that the U.S. dollar will continue to weaken for the rest of 2017–if not longer.

Posted in Breaking News, Buy, GLD, Jubak Picks Portfolio, Volatility | Tagged , , , | 2 Comments

Danaher (DHR)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
95.00

Adding water play Danaher to my Jubak Picks portfolio

In August 2015 Danaher acquired Pall for $13.8 billion. Then in 2016 Danaher spun off most of its industrial businesses into a new company called Fortiv. That left a refocused Danaher with four segments Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions. The former Pall business went into the Life Sciences segment. Through that segment Danaher is a provider of filtration, separation and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics and general industrial sectors. It’s this business that interests me as a water play in an age of capital rationing for supplies of clean water.

Posted in Breaking News, Buy, DHR, Jubak Picks Portfolio | Tagged , , | 2 Comments

Diamondback Energy, Inc. (FANG)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
130.00

My first picks for buying a piece of the Permian

What do you buy so that you’ve got a piece–and the best piece no less–of the Permian in your portfolio? You start, I think, with Pioneer Natural Resources. To me this producer is the standard for judging all other producers in the Permian. But I’ve found a second Permian picks that is, in some ways, better than Pioneer Natural Resources

Posted in Breaking News, Buy, FANG, Jubak Top 50 Portfolio | Tagged , , , , , | Leave a comment

ACADIA Pharmaceuticals Inc. (ACAD)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
55.00

Shares of Jubak Pick Acadia Pharmaceuticals pop 11% on buyout rumors

Update January 4. Shares of Acadia Pharmaceuticals (ACAD) were up 12% this morning, January 4, before closing with a gain of 11.02% to $31.94. The action came on rumors that Pfizer (PFE) or another big drug company would make a bid for the biotech on the strength of its lead drug Nuplazid

Posted in ACAD, Jubak Picks Portfolio, Update | Tagged , , | Leave a comment

Autoliv, Inc. (ALV)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
120.00

Autoliv soars on news that the company might split its auto businesses in two

Shares of Autoliv (ALV) soared today, closing up 12.26% to $127.14, on news that the company’s Board of Directors has authorized management to conduct a strategic review of splitting the current company into two new companies focused on passive auto safety and auto electronics. Autoliv is a member of my Jubak Picks portfolio. Since adding it to the portfolio on April 29, 2016, the shares are up 3.82% as of today’s close. As of this post, I’m raising the current market price of $120 to $134. Splitting up the company would release value, the market believes, by separating the slower growing passive auto safety business from the very hot auto electronics operation

Posted in ALV, Breaking News, Jubak Picks Portfolio, Update | Tagged , , , , | Leave a comment

Synaptics Incorporated (SYNA)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
115.00

Update Synaptics on deal rumors

Updated April 14. Shares of Synaptics (SYNA), a maker of touch screen technology, are soaring today on one of those unsourced stories–you know “people familiar with the matter”–that the company’s talks with a Chinese investor group are live again with a target for working out a deal by the end of April. Synaptics had started […]

Posted in SYNA | 1 Comment

Alibaba Group Holding Limited (BABA)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
195.00

What? Wait a minute! Not everything is perfect at Alibaba?

On August 17 Alibaba Group Holding (BABA) reported another blowout quarter. Non-GAAP earnings per share climbed 65% and revenue rose 56%. And… on its conference call Alibaba repeated its guidance for 45% to 49% revenue growth for fiscal 2018. Below the top line, the numbers were stunningly good too.

Posted in BABA, Breaking News, Jubak Picks Portfolio, Jubak Top 50 Portfolio, Update | Tagged , , , , | Leave a comment

The Hain Celestial Group, Inc. (HAIN)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
62.00

HAIN spikes 8.56% on news that an activist investor is pressing the company to sell itself

I’ve been waiting for this for more than a year. And so have a lot of other investors and traders from the market reaction today. Shares of Hain Celestial Group (HAIN) jumped 8.56% today on news that activist investor Engaged Capital had accumulated almost 10% of the company’s shares and was demanding that the company put itself up for sale. Engaged Capital has nominated seven candidates for the company’s board.

Posted in Breaking News, HAIN, Jubak Picks Portfolio, Update | Tagged , , , | Leave a comment

WisdomTree Japan Hedged Real Estate ETF (DXJR)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
32.00

Update Wisdom Tree Japan Hedged Real Estate ETF

Update: March 22, 2016. When I added Wisdom Tree Japan Hedged Real Estate ETF (DXJR) to my Jubak Picks portfolio back in December 2014, my idea was that investment flows from China into cheaper (and safer from government eyes) Tokyo real estate plus development for the 2020 Olympics would push prices in the Tokyo real […]

Posted in DXJR | 1 Comment

HDFC Bank Limited (HDB)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
62.00

Buy HDFC (HDB)

Only the third largest bank in India, but the best run under managing director Aditya Pura, the former CEO of Citibank Malaysia. Because HDFC’s base of retail deposits–from a network of 746 branches in 329 cities serving 10 million customers–provides about 40% of the capital it lends out, the bank has been able to maintain […]

Posted in Buy, HDB | Leave a comment

Visa Inc. (V)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
108.00

Visa: It you can’t beat ’em, buy ’em

Visa (V) is defending its turf in the financial processing market by buying and/or partnering with the new generation of fintech companies. Visa’s latest deal is the purchase of a stake of less than 10% in Finland’s Klarna, The still-private company recently became the largest European fintech player to get a banking license.

Posted in Breaking News, Jubak Picks Portfolio, Update, V | Tagged , , , | Leave a comment

Itau Unibanco Holding S.A. (ITUB)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
18.00

Itau Unibanco gains on interest rate cut but advance in Brazilian stocks is muted by arrest of another big-fish politico

Yesterday the Banco Central do Brasil reduced Brazil’s benchmark interest rate for the first time in four years. The cut, 25 basis points to 14%, was less than the 50 basis points the market was hoping for. But the dream is that it will be just the first of many reductions in the benchmark rate. The last time the Selic rate was reduced was in October 2012 when the bank cut to 7.25%. There’s obviously a lot of room for cuts here–if Brazil’s economy will cooperate. So why has the response been so relatively modest?

Posted in ITUB, Jubak Picks Portfolio, Update | Tagged , , , , , | Leave a comment

Ionis Pharmaceuticals, Inc. (IONS)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
65.00

Good news for Ionis pipeline from this trial–upping target price to $65

Sometimes the importance of a clinical trial extends way beyond the specific drug under study. That’s the case with the Phase II data recently released by Ionis for FIXRx. The trial did show efficacy in the treatment of kidney disease. But the most important results in the trial were what it didn’t show. There was no evidence that patients receiving the drug as part of the trial saw any reduction in platelet levels and no treatment-related bleeding events

Posted in IONS, Jubak Picks Portfolio, Update | Tagged , , , , , | 2 Comments

Incyte Corporation (INCY)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
142.00

Incyte up on positive trial results

Shares of Incyte (INCY) are up 7.1% as of 12:30 p.m. New York time on data released before the June meeting of the American Society of Clinical Oncology showing that Incyte’s epacadostat, which is an IDO inhibitor, has proved effective when used in combination with Merck’s (MRK) Keytruda and Bristol-Myers Squibb’s (BMY) Opdivo.

Posted in Breaking News, INCY, Jubak Picks Portfolio, Update | Tagged , , , , | Leave a comment

Cheniere Energy, Inc. (LNG)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
58.00

Natural gas stocks up today on rise in LNG prices in Asia

Shares of natural gas producers and liquefied natural gas exporters climbed strongly today as prices for liquefied natural gas in Asia rose to s seven-month high in reaction to the damaged inflicted on Gulf Coast terminals by Hurricane Harvey. It didn’t hurt prices either that Chevron’s huge Gorgon liquefaction plant in Australia is shut and that other Australian plants expected to be in operation now face delays. Natural gas itself rose just 0.21% today to $3.07 per million BTUs. But shares of Chesapeake Energy (CHK), the second largest U.S. natural gas producer, and of Cheniere Energy (LNG), the first company to secure a completely unrestricted license to export liquefied natural gas, climbed 4.19% and 3.07% , respectively.

Posted in Breaking News, CHK, Jubak Picks Portfolio, Jubak Top 50 Portfolio, LNG | Tagged , , | Leave a comment

Targa Resources Corp. (TRGP)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
60.00

Targa Resources can climb from here but the attraction is the 8% dividend

Last year prices for natural gas liquids fell even faster than oil prices did. Hard as that may be to believe. Which is why the price for shares of Targa Resources are down 23.16% for the last twelve months This year natural gas liquids have recovered faster than oil prices. Which is why the shares of this company, which runs a network of pipelines and storage facilities heavy on the transport of natural gas liquids, are up 62.66% for 2016 through September 2.

Posted in Breaking News, TRGP, Update | Tagged , , , | Leave a comment

Xylem Inc. (XYL)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
63.00

Xylem raises guidance for fiscal 2017 after slight earnings beat in second quarter

On August 1 Xylem (XYL) reported second quarter earnings of 59 cents a share (excluding one-time items), beating Wall Street earnings estimates by 2 cents a share. Thanks to recent acquisitions revenue of $1.16 billion climbed 24.9% year over year, slightly missing the analyst consensus of $1.17 billion. And the company raised guidance for 2017 to earnings of $2.30 to $2.40 a share

Posted in Breaking News, Jubak Picks Portfolio, Update, XYL | Tagged , , , , | Leave a comment

Statoil ASA (STO)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
24.00

Statoil’s second quarter: Better than the average oil company

Update: July 28, 2015. Statoil (STO) reported second quarter results today (July 28) that beat consensus estimates on both earnings (NOK3.15 a share vs. the NOK1.62 consensus) and revenue (NOK138.5 billion vs. NOK124.8 billion analyst consensus.) That doesn’t mean Statoil has found some way to magically sell oil for a higher price than competitors. Second […]

Posted in STO | Leave a comment

MGM Resorts International (MGM)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
26.00

Two typhoons don’t dent casino revenue growth in Macao

Casino revenue in Macao climbed by a year over year 20% in August, marking a 13th consecutive month of growth–despite two typhoons the left half of the city without power and water for as many as four days. Shares of MGM Resorts International (MGM), which is due to open a new casino on the Cotai Strip at the end of 2017, are up 10.84% from August 17 to 3 p.m. today, September 6.

Posted in Breaking News, Jubak Picks Portfolio, MGM | Tagged , , , | Leave a comment

OncoGenex Pharmaceuticals, Inc. (OGXI)
Symbol Date Added Price Then Target Price Price Now Jubak's Gain/Loss (%)
22.00

OncoGenex pops today on hopes for major cancer drug news tomorrow

Shares of biotech OncoGenex (OGXI) were up 8.9% today, March 10 at the close in New York. Why? Because March 10 is the day before March 11. The company is scheduled to report fourth quarter results on March 11 after the close of the New York market and speculation today is that the company will […]

Posted in OGXI | 5 Comments

Fixed Code

Autoliv soars on news that the company might split its auto businesses in two

Shares of Autoliv (ALV) soared today, closing up 12.26% to $127.14, on news that the company’s Board of Directors has authorized management to conduct a strategic review of splitting the current company into two new companies focused on passive auto safety and auto electronics. Autoliv is a member of my Jubak Picks portfolio. Since adding it to the portfolio on April 29, 2016, the shares are up 3.82% as of today’s close. As of this post, I’m raising the current market price of $120 to $134. Splitting up the company would release value, the market believes, by separating the slower growing passive auto safety business from the very hot auto electronics operation

read more

Natural gas stocks up today on rise in LNG prices in Asia

Shares of natural gas producers and liquefied natural gas exporters climbed strongly today as prices for liquefied natural gas in Asia rose to s seven-month high in reaction to the damaged inflicted on Gulf Coast terminals by Hurricane Harvey. It didn’t hurt prices either that Chevron’s huge Gorgon liquefaction plant in Australia is shut and that other Australian plants expected to be in operation now face delays. Natural gas itself rose just 0.21% today to $3.07 per million BTUs. But shares of Chesapeake Energy (CHK), the second largest U.S. natural gas producer, and of Cheniere Energy (LNG), the first company to secure a completely unrestricted license to export liquefied natural gas, climbed 4.19% and 3.07% , respectively.

read more

Adding a gold ETF on today’s drop in the metal on hurricane, North Korea relief

I’m adding the SPDR Gold Shares ETF (GLD) to my Jubak Picks and Volatility portfolios today. Gold has sold off today with worries over a new missile test from North Korea in abeyance. And with traders relieved–and apparently surprised–to discover that Hurricane Irma didn’t wash Florida out to sea over the weekend. As I have noted over the last few days the likelihood is that the U.S. dollar will continue to weaken for the rest of 2017–if not longer.

read more

Nothing but good news for markets from European Central Bank today

At today’s meeting the European Central Bank announced that it would leave interest rates in negative territory and continue to buy debt assets at the current monthly rate. In his post-meeting press conference ECB president Mario Draghi noted that despite an increase in economic growth in the EuroZone to 2.3% year over year in the second quarter, the bank has yet to see a sustained increase in the rate of inflation that would lead to a change in policy.

read more

Two typhoons don’t dent casino revenue growth in Macao

Casino revenue in Macao climbed by a year over year 20% in August, marking a 13th consecutive month of growth–despite two typhoons the left half of the city without power and water for as many as four days. Shares of MGM Resorts International (MGM), which is due to open a new casino on the Cotai Strip at the end of 2017, are up 10.84% from August 17 to 3 p.m. today, September 6.

read more

Hurricane Harvey is demonstrating the new world of oil prices–and I’m selling refiner Marathon Petroleum into the storm

With Hurricane Harvey barreling down on the Gulf Coast complex of refineries and oil terminals, you might have expected the price of gasoline to rise yesterday, August 24, on fears of a shutdown of supply. And it did. The price of gasoline climbed 2.35% yesterday on the commodities market. The price of oil fell, though, with West Texas Intermediate falling 1.63% on the day.

read more

Xylem raises guidance for fiscal 2017 after slight earnings beat in second quarter

On August 1 Xylem (XYL) reported second quarter earnings of 59 cents a share (excluding one-time items), beating Wall Street earnings estimates by 2 cents a share. Thanks to recent acquisitions revenue of $1.16 billion climbed 24.9% year over year, slightly missing the analyst consensus of $1.17 billion. And the company raised guidance for 2017 to earnings of $2.30 to $2.40 a share

read more

One less worry hanging over shares of Jubak Pick Cheniere Energy

One worry hanging over shares of Cheniere Energy (LNG), the first company to get an unrestricted license to export liquified natural gas (LNG) to any country in the world, was what would happen if some of the customers that signed a long-term contract to buy LNG from Cheniere decide that they wanted to break its contract because of lower prices for natural gas. Well, now we have one example of exactly what happens–nothing. Which is good news for investors who own Cheniere.

read more

HAIN spikes 8.56% on news that an activist investor is pressing the company to sell itself

I’ve been waiting for this for more than a year. And so have a lot of other investors and traders from the market reaction today. Shares of Hain Celestial Group (HAIN) jumped 8.56% today on news that activist investor Engaged Capital had accumulated almost 10% of the company’s shares and was demanding that the company put itself up for sale. Engaged Capital has nominated seven candidates for the company’s board.

read more

Two big deals for Cheniere Energy

Cheniere Energy (LNG) has a significant first-mover advantage, I argued upon picking this stock for my Jubak Picks portfolio, since it was the first U.S. company to get a unrestricted permit to export liquified natural gas. Turning that advantage into revenue and earnings, however, always depended on Cheniere’s ability to move sales from the spot market to long term contracts. The company struck two more deals this past week.

read more

Adding water play Danaher to my Jubak Picks portfolio

In August 2015 Danaher acquired Pall for $13.8 billion. Then in 2016 Danaher spun off most of its industrial businesses into a new company called Fortiv. That left a refocused Danaher with four segments Life Sciences; Diagnostics; Dental; and Environmental & Applied Solutions. The former Pall business went into the Life Sciences segment. Through that segment Danaher is a provider of filtration, separation and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics and general industrial sectors. It’s this business that interests me as a water play in an age of capital rationing for supplies of clean water.

read more

Alibaba blows the top out on growth forecast; raising my target price

Yesterday, June 8, Alibaba (BABA) forecast that revenue would climb by 49% for fiscal 2018. That’s a solid 10 percentage points above the recent projection from Wall Street analysts. The New York traded ADRs climbed almost 10% on the news yesterday. They’re off 2.04% today against the background of a 1.80% drop in the NASDAQ Composite as a whole.

read more

Incyte up on positive trial results

Shares of Incyte (INCY) are up 7.1% as of 12:30 p.m. New York time on data released before the June meeting of the American Society of Clinical Oncology showing that Incyte’s epacadostat, which is an IDO inhibitor, has proved effective when used in combination with Merck’s (MRK) Keytruda and Bristol-Myers Squibb’s (BMY) Opdivo.

read more

Cheniere Energy pops on possibility of increased China exports

Earlier this week the Trump administration announced that it had reached an agreement with China to increase market access for U.S. energy companies. Today Cheniere Energy (LNG) noted that it has had extensive negotiations with Chinese state-owned companies about increasing shipments of liquefied natural gas (LNG) to China. Cheniere has sold nine cargoes of LNG on the spot market to China since it began exporting liquified natural gas in February 2016. The goal now for the company is moving from sales on the spot market to long-term contracts. On the news shares of Cheniere are up 3.24% as of 3:30 p.m. New York time.

read more

Sell Bristol-Myers Squibb before Thursday’s earnings report

I’m selling Bristol-Myers Squibb (BMY) out of my Jubak Picks portfolio ahead of Thursday’s report of first quarter earnings. I’m afraid that earnings will confirm what monthly sales reports from Bristol-Myers and competitors have outlined: That the company’s Opdivo cancer drug continues to lose market share among lung cancer treatments to drugs from Merck (MRK) and Roche Holding (RHHBY). That might not be a big deal–troubles with one drug, phfff–at another drug company or at another time, but Opdivo is critical to Bristol-Myers establishing the credibility of future growth with investors. Wall Street sees lung cancer as an estimated $10 billion to $15 billion market opportunity.

read more

Incyte dropped 10.5% yesterday on FDA drug “rejection”: Here’s what’s actually going on (and why you shouldn’t sell)

I know the headlines on Friday said that the U.S. Food and Drug Administration had “rejected” Olumiant (known more frequently until recently as baricitinib), a new drug for rheumatoid arthritis from Eli Lilly (LLY) and research lead Incyte Corp (INCY.) And on those headlines shares of Incyte dropped $14.77 a share on Monday to $126.07 from $140.84. The shares trickled lower to $125.84, down 0.13% today. What you need to know about this story is that the FDA didn’t reject baricitinib.

read more

Sell Vulcan Materials–I don’t see an infrastructure package this year

With the Senate about to go nuclear as Republicans change the Senate rules so they can avoid a Democratic filibuster and send Neil Gorsuch to the Supreme Court, any small chance that Democrats would work with Republicans to pass some version of President Trump’s $1 trillion infrastructure spending plan has gone from slim to none. Think Democrats will have any inclination to vote with Trump after seeing Republicans stonewall President Obama’s nominee for the court and then ram Gorsuch down their throats? And Trump needs Democratic votes because substantial numbers of the members of his own party in Congress will vote against infrastructure spending.

read more

Incyte is on the way to becoming a complete drug company–or an expensive acquisition candidate

Usually with a biotech stock you trade the present for the future: no revenue now but the promise of big revenue to come. Incyte’s (INCY) most recent quarter, reported on February 14, doesn’t require that trade off. Which means investors should be asking a different set of questions about the future of the company. For the quarter revenue climbed to $326.5 million, up 33.9% year over year.

read more

What’s the “quid” for Softbank’s “quo”?

Softbank (SFTBY) has been in the headlines a lot recently–usually after an announcement by President-elect Donald Trump. There was Softbank CEO and chairman Masayoshi Son emerging after a meeting with Trump at Trump Tower to announce that Softbank would invest $50 billion (of $100 billion raised in a new venture fund) in the United States and create 50,000 jobs in the U.S

read more

Raising my target price on Jubak Picks Cheniere Energy

The Cheniere Energy story is pretty simple. The company got the first license to export liquified natural gas from the United States, locked in long-term contracts for its Sabine Pass and Corpus Christi terminals, and then waited for revenue to flow in as the individual production trains at the two plants kicked in. What investors needed was patience–and sometimes strong nerves–as they contemplated the mountain of debt that Cheniere had used to fund its facilities and the fact that natural gas prices had tanked since the heady days when the company began to build its facilities. The third quarter of 2016, then marked something of a turning point for the company.

read more

Stillwater Mining up 18% on acquisition news

Stillwater Mining (SWC) has agreed to an acquisition offer from South Africa’s Sibanye Gold (SBGL.) The proposed purchase price of $2.2 billion works out to $18.00 a share for the largest primary producer of platinum and palladium outside of South Africa and Russia. The shares are trading at $17.42 as of 1:30 p.m.New York time on Friday. That price, slightly below the offer, indicates that the market isn’t anticipating a competing bid.

read more

My second Trump administration stock pick–this time it’s infrastructure

When big macro news comes down the pike that promises to change the fundamentals in a sector, frequently the stocks that rally hardest are those that belong to the most “endangered” companies.Which doesn’t mean those are the shares that you want to buy after the first big enthusiasm starts to be colored by a bit of reality. We saw that in the rally in the energy sector after OPEC announced an agreement to cut oil production when shares of ocean drilling companies with their high leverage to oil prices and shaky balance sheets soared while more fundamentally sound land drilling stocks lagged. Ocean driller Transocean (RIG) is up 43.68% in the last month whereas shares of diversified oil services technology leader Schlumberger (SLB) is up just 5.87.And we’ve seen it in materials stocks after Donald Trump’s victory in the presidential election.

read more

Good news for Ionis pipeline from this trial–upping target price to $65

Sometimes the importance of a clinical trial extends way beyond the specific drug under study. That’s the case with the Phase II data recently released by Ionis for FIXRx. The trial did show efficacy in the treatment of kidney disease. But the most important results in the trial were what it didn’t show. There was no evidence that patients receiving the drug as part of the trial saw any reduction in platelet levels and no treatment-related bleeding events

read more

More good news for Jubak Pick Incyte–raising target price to $125

Incyte (INCY) has been one of the big movers in the biotech rally after Donald Trump’s victory in the November 8 presidential election. The stock is up 26.7% from the close on November 3 to the close today, November 17. (Incyte is a member of my Jubak Picks portfolio. The shares are up 126.2% since I added them to the portfolio on April 17, 2014.) The latest bump–a gain of 4.77% today–came on news that…

read more

Financial markets decide the S&P earnings recession is over–time to sell my S&P short ETF

It looks like the third quarter saw the end of the long earning recession for Standard & Poor’s 500 companies. That recession had seen earnings for the S&P 500 companies drop for five straight quarters. With more than 90% of the S&P 500 companies reporting, third quarter earnings are up 2.9% year over year, according to FactSet. At the beginning of earnings season, Wall Street analysts had expected earnings to fall for a sixth straight quarter, this time by 2.4%.

read more

Acadia Pharmaceuticals is my first Trump stock pick

The big test for Acadia Pharmaceuticals (ACAD) this quarter certainly wasn’t earnings. As an early stage biotech losses are expected and that’s exactly what the company delivered when it reported third quarter results on November 7. The loss came to 61 cents a share, four cents a share worse than Wall Street expected. But this was the first quarter of sales for the company’s new drug, Nuplazid

read more

Bristol-Myers continues to make up lost ground after August failure of Opdivo trial

Back on August 8 Bristol-Myers Squibb (BMY) announced that its key immuno-oncology drug Opdivo had failed to demonstrate its efficacy in a trial for treating lung cancer. At the time I characterized this particular trial as a part of a go-for-broke strategy that would have given Opdivo a huge boost in the market against Merck’s (MRK) Keytruda, the main competitor to Opdivo at the moment in the hot market for drugs that fight cancer by enlisting the body’s immune system. Bristol-Myers had designed its Opdivo trial to demonstrate the drug’s efficacy for a larger pool of potential patients than Merck’s drug addressed. Which would have increased the size of Opdivo’s market if the trial had been successful. But it wasn’t.

read more

MGM Resorts still has more upside from here

MGM Resorts International (MGM) hit a new 52-week high during intraday trading on November 7. The stock is now up 119.96% since I added it to my Jubak Picks portfolio back on May 4, 2012. Shouldn’t I just take my profits and run? Well, Yes if all the catalysts that would drive this stock higher are exhausted. No, if they’re not. Which is it with MGM Resorts?

read more

Selling my Treasury ETF because my scenario on global central bank policy was wrong

When I bought shares of the iShares 7-10 Year Treasury Bond ETF (IEF) back on June 28, 2016, it was in the belief that the Federal Reserve would raise interest rates (as early as September or as late as December) while other central banks remained committed to their own programs of asset purchases and lower interest rates. That disjunction would, I thought, bring money looking for a slightly better return and a slightly stronger currency into U.S. assets, such as Treasuries. There was a good chance, I figured, that under that scenario even when the Fed raised the short-term rates it controls, that long-term and medium term Treasury bond yields would fall on higher demand for those assets. That scenario looks to me now to be wrong.

read more

Jim’s Daily Email Alerts:

Every post from Jubak Picks straight to your mailbox. And they're free!

Get Even More Jim!

  • • More profiles of hot (and cold) sectors
  • • More strategies for profiting from volatility
  • • More about macro trends driving the market
  • • More on where the market is heading – short-, medium- and long-term – including a Saturday Night Quarterback look at the week ahead!

Subscribe now for a year for just $199

Stock Trader's Almanac 2016 Best Investing Book